Asthma Clinical Trial
Official title:
Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT)
The objective of this study was to evaluate the use of high frequency chest wall oscillation (HFCWO) early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD).
Acute asthma and chronic obstructive pulmonary disease (COPD) are exceedingly common, which
together account for nearly 1 million hospitalizations each year in the United States alone.
Beta agonists, anticholinergics, and corticosteroids delivered in aerosolized forms (via
respiratory inhalers or nebulization) are recommended in the treatment of acute asthma and
COPD. These medications rely on deposition into distal airspaces to suppress airway
inflammation or promote bronchodilation. Unfortunately, excessive mucous production and
impaired airway mucociliary clearance can lead to airway plugging, and thereby reduce the
deposition of and response to aerosolized medications. These considerations highlight the
need for therapies that clear airways of mucus in the acute management of asthma and COPD.
High frequency chest wall oscillation (HFCWO) creates high velocity, low amplitude
oscillatory airflows when applied through a pneumatic vest worn over the thorax, and is used
for airway mucus clearance in patients with cystic fibrosis, bronchiectasis, and
neuromuscular disorders.
This was a randomized, multi-center, double-masked phase II clinical trial of active or sham
treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four
academic medical centers. Patients received active or sham treatment for 15 minutes three
times a day for four treatments. Medical management was standardized across groups. The
primary outcomes were patient adherence to therapy after four treatments (minutes used/60
minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea
score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum
volume, and forced expired volume in 1 second.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|